Skip to content

Assessment of Response to Neo-adjuvant Chemotherapy for Patients With a Locally Advanced Breast Cancer With 3D Elastography (Shear Wave), NEOELASTO

3D Elastography (Shear Wave) : Assessment of Response to Neo-adjuvant Chemotherapy (NACT) : in Vivo Quantification, for Patients With a Locally Advanced Breast Cancer.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02834494
Acronym
NEO-ELASTO
Enrollment
140
Registered
2016-07-15
Start date
2016-02-22
Completion date
2020-09-09
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Neoplasms

Keywords

locally advanced breast cancer, neoadjuvant chemotherapy

Brief summary

Assess the accuracy of the sequential measurements by 3D Shear Wave Elastography (SWE) for predicting histological response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.

Interventions

PROCEDURE3D Shear Wave Elastography (SWE)

Ultrasound imaging with Elastography will be performed at the inclusion (T0), after course 1 and course 2 respectively with anthracyclines, at the end of anthracycline treatment and at the end of taxane treatment.

BIOLOGICALBiopsy

Optional biopsy of breast tumor under neoadjuvant chemotherapy after the course 2 of anthracycline.

Sponsors

Institut Curie
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Infiltrating Breast Cancer untreated and/or locally advanced (stages I (T1c), IIa IIb, IIIa, IIIb, IIIc of UICC classification), whatever histological type. * Neo-adjuvant chemotherapy decided.(Anthracyclines, taxanes and, for tumors overexpressing human epidermal growth factor receptor 2 (HER2) protein, targeted recombinant humanized monoclonal antibodies) * Index tumor whose dimensions are between 10 to 50 mm. Multifocality, and/or multicentricity and/or bilaterality accepted (maximum 2 tumors by breast et tumors well differentiated from each other). * Patients aged at least 18 years old at diagnosis * Full results conventional breast exams available and no reason to achieve MRI breast exam * Patient explanation given and consent information signed

Exclusion criteria

* Pregnant or during lactation * Personal history of ipsilateral breast cancer (ipsilateral recurrence or second cancer in the same breast). * Patient carrier of cosmetic breast implants * Person deprived of liberty or under guardianship * Contraindication for receiving neo-adjuvant chemotherapy for any medical reason * Inability to submit to medical monitoring of the trial for reasons of geography, social or psychological.

Design outcomes

Primary

MeasureTime frameDescription
Assess the accuracy of the sequential measurements by 3D Shear Wave Elastography (SWE) for predicting histological response to neoadjuvant chemotherapyup to 32 monthsMeasure of the tumor prior to neoadjuvant chemotherapy (T0), at T1 and T2(1stand 2nd courses of anthracycline), at mid-treatment between anthracycline and taxane chemotherapy (Tmi), at the end of chemotherapy before surgery (Tfin).

Secondary

MeasureTime frameDescription
peritumoral environmental elasticity propertiesup to 32 monthsUse technic Supersonic Shear Imaging (Explorer, Supersonic Imagine).
Reliable early biomarker of histological response.up to 32 monthsEstimate under chemotherapy if early changes in tumor's elasticity can provide a reliable early biomarker of histological response.
tumor volume changes under treatment by 3D ultrasoundup to 32 monthsEstimate tumor volume changes under treatment by 3D ultrasound and Compare with measurements obtained by other conventional imaging methods currently used for monitoring patients under neoadjuvant chemotherapy
Compare changes in tumor elasticity under chemotherapy to variables obtained by other imaging modalities (Breast MRI) performed in clinical routineup to 32 months
Elastic properties before treatment (especially ratio between tumor and glandular breast or fat tissues close to the tumors)up to 32 monthsUse technic Supersonic Shear Imaging.
Compare changes in tumor volume to histological response (Gold Standard : surgery after neoadjuvant chemotherapy according to Residual Cancer Burden scoreup to 32 months
Compare predictive value (semi-quantitative et quantitative measurements) of tumor elasticityup to 32 months
Assess vascular shape and its evolution under treatment by Ultrasensitive Doppler technic Ultra-Fast Dopplerup to 32 months
Compare tumor elasticity to conventional histological parameters6 weeksFor the additional biopsy (optional) under neoadjuvant chemotherapy at T2, correlation elastography to pathological parameters of peritumoral environment by analyzing conventional histological parameters.
Compare changes in tumor elasticity under neoadjuvant chemotherapy to changes in diffusion apparent coefficient by using technic Supersonic Shear Imaging (Explorer, Supersonic Imagine).up to 32 months

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026